Structural basis for surface activation of the classical complement cascade by the short pentraxin C-reactive protein.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
10 Sep 2024
Historique:
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 6 9 2024
Statut: ppublish

Résumé

Human C-reactive protein (CRP) is a pentameric complex involved in immune defense and regulation of autoimmunity. CRP is also a therapeutic target, with both administration and depletion of serum CRP being pursued as a possible treatment for autoimmune and cardiovascular diseases, among others. CRP binds to phosphocholine (PC) moieties on membranes to activate the complement system via the C1 complex, but it is unknown how CRP, or any pentraxin, binds to C1. Here, we present a cryoelectron tomography (cryoET)-derived structure of CRP bound to PC ligands and the C1 complex. To gain control of CRP binding, a synthetic mimotope of PC was synthesized and used to decorate cell-mimetic liposome surfaces. Structure-guided mutagenesis of CRP yielded a fully active complex able to bind PC-coated liposomes that was ideal for cryoET and subtomogram averaging. In contrast to antibodies, which form Fc-mediated hexameric platforms to bind and activate the C1 complex, CRP formed rectangular platforms assembled from four laterally associated CRP pentamers that bind only four of the six available globular C1 head groups. Potential residues mediating lateral association of CRP were identified from interactions between unit cells in existing crystal structures, which rationalized previously unexplained mutagenesis data regarding CRP-mediated complement activation. The structure also enabled interpretation of existing biochemical data regarding interactions mediating C1 binding and identified additional residues for further mutagenesis studies. These structural data therefore provide a possible mechanism for regulation of complement by CRP, which limits complement progression and has consequences for how the innate immune system influences autoimmunity.

Identifiants

pubmed: 39240968
doi: 10.1073/pnas.2404542121
doi:

Substances chimiques

C-Reactive Protein 9007-41-4
Phosphorylcholine 107-73-3
Complement C1 0
Liposomes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2404542121

Subventions

Organisme : EC | European Research Council (ERC)
ID : 759517

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Dylan P Noone (DP)

Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Marjolein M E Isendoorn (MME)

Leiden Institute of Chemistry, Gorlaeus Laboratory, Leiden University, 2333 CC Leiden, The Netherlands.

Sebastiaan M W R Hamers (SMWR)

Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Mariska E Keizer (ME)

Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Jip Wulffelé (J)

Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Tijn T van der Velden (TT)

Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Douwe J Dijkstra (DJ)

Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Leendert A Trouw (LA)

Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Dmitri V Filippov (DV)

Leiden Institute of Chemistry, Gorlaeus Laboratory, Leiden University, 2333 CC Leiden, The Netherlands.

Thomas H Sharp (TH)

Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
School of Biochemistry, University of Bristol, Bristol BS8 1TD, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH